



AJOONI BIOTECH LIMITED

Regd. Office: D-118, Industrial Area, Phase VII, Mohali-160055 (Pb.)

Corp Office: H.No 1769, Phase 3B2, Mohali-160059

Phone: 0172-5020758-69 Website: www.ajoonibiotech.com

E-mail: ajooni.biotech@gmail.com / info@ajoonibiotech.com

CIN: L85190PB2010PLC040162

28/01/2025

To,
National Stock Exchange of India Ltd
Exchange Plaza, Plot no. C/1, G Block,
Bandra-Kurla Complex, Bandra (E)
Mumbai - 400051

Dear Sir / Madam,

Subject : Intimation of issuance of Corrigendum to the Notice of the 01st Extra Ordinary General Meeting

SYMBOL: AJOONI

In reference to the application submitted on 08/01/2025 for "In-principle approval" prior to issue and allotment of 5,00,00,000 convertible warrants on preferential basis under Regulation 28(1) of the SEBI (LODR) Regulations, 2015, The Corrigendum is being issued in connection to the Notice of Extra Ordinary General Meeting dated January 03, 2025 which has been sent to all the shareholders and published in following newspapers viz., "Financial Express" (in English all editions)) and "Desh Sewak" (in Regional Punjabi Language) dated January 27,2025. Copy of Corrigendum is attached for your reference.

You are requested to take the above information on records.

Thanking You,
Yours Truly,
For Ajooni Biotech Limited

Swati Vijan
Company Secretary
A39179

AJOONI BIOTECH LIMITED
CIN: L85190PB2010PLC040162

Registered Office: D-118, Industrial Area Phase-7, Mohali, Mohali, Punjab - 160059
Email: ajooni118@gmail.com Website: www.ajoonibiotech.com Contact: +91-172-5020762

CORRIGENDUM TO NOTICE OF 01ST EXTRA ORDINARY GENERAL MEETING WHICH IS SCHEDULED TO BE HELD ON 03.01.2025.

This Corrigendum is being issued in connection to the Notice of Extra Ordinary General Meeting dated January 03, 2025 which has been sent to all the shareholders on January 08, 2025. The following alterations/modifications in the Notice are hereby notified through this corrigendum to all the shareholders:

This is to notify you that the following typographical errors have been amended, clarified, and corrected in the Explanatory Statement for Item No.3.

It is hereby clarified that this statement be read as under:

Explanatory Statement of Item No.3

b. Objects of the Preferential Allotment:

Subject to applicable laws and regulations, our Company intends to use the Gross Proceeds to Preferential Issue (in whole or part) one or more, or any combination of the following:

- (a) Working Capital requirements of Company, meeting various operational expenditure of the Company;
- (b) Capital expenditure requirements of Company, meeting various capital expenditure of the Company;
- (c) Financing / investing of business opportunities, strategic initiatives;
- (d) General corporate purpose; and
- (e) Issue related expenses

The Proceeds are proposed to be deployed towards the purpose set out above and not proposed to be utilized towards any specific project. Accordingly, the requirement to disclose: (i) the break-up of cost of the project, (ii) means of financing such project, and (iii) proposed deployment status of the proceeds at each stage of the project, are not applicable.

The requirement stipulated by NSE Notice No. NSE/CML/2023/51 dated July 05,2023 with respect to the additional disclosures for objects of the issue is not applicable as the issue size of the preferential issue is less than Rs. 100 Crore.

This corrigendum should be read in continuation of and in conjunction with the notice. The Corrigendum to the notice is also being placed on Company's website www.ajoonibiotech.com

All other contents of the notice remain unchanged.

For Ajooni Biotech Limited

Place: Punjab
Date: 27/01/2025

JASJOT
SINGH
Digitally signed
by JASJOT
SINGH
Date: 2025.01.28
16:22:37 +05'30'

SD/-
Swati Vijan
Company Secretary